EGFR Exon 20 insertion (A763_Y764insFQEA) mutant NSCLC is not identified by Roche Cobas Version 2 tissue testing but has durable intracranial and extracranial response to osimertinib
dc.contributor.author | Coleman, N. | |
dc.contributor.author | Woolf, David K | |
dc.contributor.author | Welsh, L. | |
dc.contributor.author | McDonald, F. | |
dc.contributor.author | MacMahon, S. | |
dc.contributor.author | Yousaf, N. | |
dc.contributor.author | Popat, S. | |
dc.date.accessioned | 2020-11-16T07:49:05Z | |
dc.date.available | 2020-11-16T07:49:05Z | |
dc.date.issued | 2020 | en |
dc.identifier.citation | Coleman N, Woolf D, Welsh L, McDonald F, MacMahon S, Yousaf N, et al. EGFR Exon 20 Insertion (A763_Y764insFQEA) Mutant NSCLC Is Not Identified by Roche Cobas Version 2 Tissue Testing but Has Durable Intracranial and Extracranial Response to Osimertinib. J Thorac Oncol. 2020;15(10):e162-e5. | en |
dc.identifier.pmid | 32981603 | en |
dc.identifier.doi | 10.1016/j.jtho.2020.05.006 | en |
dc.identifier.uri | http://hdl.handle.net/10541/623363 | |
dc.description.abstract | None | en |
dc.language.iso | en | en |
dc.relation.url | https://dx.doi.org/10.1016/j.jtho.2020.05.006 | en |
dc.title | EGFR Exon 20 insertion (A763_Y764insFQEA) mutant NSCLC is not identified by Roche Cobas Version 2 tissue testing but has durable intracranial and extracranial response to osimertinib | en |
dc.type | Article | en |
dc.contributor.department | Lung Unit, The Royal Marsden Hospital, Chelsea, London, United Kingdom; Institute of Cancer Research, Sutton, London, | en |
dc.identifier.journal | Journal of Thoracic Oncology | en |
dc.description.note | en] |